Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab vs placebo in newly diagnosed type 1 diabetes (Stage 3)
ChiCTR2600122711Phase 3Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Teplizumab arm with Placebo arm (2 arms). Primary endpoints: Change in glycated hemoglobin (HbA1c) from baseline to week 52, Total days without prandial insulin use from baseline to week 52 and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ChiCTR2600122711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122711.